Kamada Reports Financial Results for the Second Quarter and

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Kamada Reports Financial Results for the Second Quarter and First Six Months of 2016

Total Revenues for First Half of 2016 Grew 20% to $33.9 Million vs. First Half of 2015

Proprietary Products Revenue Grew 46% to $23.2 Million in First Half of 2016 vs. First Half of 2015

Company Reiterates 2016 Revenue Guidance and 2017 Sales Target of $100 Million

Conference Call Today at 8:30am Eastern Time

NESS ZIONA, Israel, Aug. 02, 2016 (GLOBE NEWSWIRE) -- Kamada Ltd. (Nasdaq: KMDA ) (TASE: KMDA ), a plasma-derived protein therapeutics company focused on orphan indications, announced financial results for the three and six months ended June 30, 2016. 

“We are very pleased with our financial performance and achievements to date in 2016,” said Amir London, Chief Executive Officer of Kamada, Ltd.  “The 20 percent growth in total revenues in the first half of 2016 as compared to the first half of 2015 was driven by a 46 percent increase in sales from our Proprietary Products Segment.  Importantly, the number of patients treated with GLASSIA® in the U.S. through our collaboration with Shire continues to increase strongly and provides us with confidence in our ability to achieve our 2016 revenue guidance of $75 to $80 million, and our $100 million sales target in 2017.  This revenue growth and our improved profitability as reflected in our improved gross profit and positive Adjusted EBITDA reinforces our plan to breakeven 2017.”

Financial Highlights for the Three-Months Ended June 30, 2016:

  • Total revenues were $19.1 million, compared to $19.2 million in the same period of 2015
  • Gross profit was $5.6 million, compared to $3.6 million in the same period of 2015
  • Gross margin increased to 30% from 19% in the same period of 2015
  • Net loss was $1.6 million, or $0.04 per share, compared to $2.3 million, or $0.06 per share, in the same period of 2015

Financial Highlights for the Six-Months Ended June 30, 2016:

  • Total revenues were $33.9 million, compared to $28.2 million in the same period of 2015, an increase of 20 percent
  • Revenues from the Proprietary Product Segment were $23.2 million, as compared to $15.9 million in the same period of 2015, an increase of 46 percent
  • Gross profit was $10.4 million, compared to $4.0 million in the same period of 2015
  • Gross margin increased to 31% from 14% in the same period of 2015
  • Adjusted net loss was $3.2 million, or $0.11 per share, compared to adjusted net loss of $6.6 million, or $0.21 per share, in the same period of 2015

Recent Corporate Highlights:

  • Received a milestone payment from Chiesi upon the filing of a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) for inhaled alpha-1 antitrypsin (AAT) for the treatment of AAT deficiency (AATD).  Chiesi Farmaceutici is Kamada’s exclusive marketing and distribution partner for its inhaled AAT for the treatment of AATD in Europe. 
  • Received a milestone payment from Baxalta (now part of Shire) as a result of Baxalta achieving an undisclosed sales milestone for Glassia®, Kamada's intravenous (IV) AAT treatment.   
  • FDA approved an expanded label for GLASSIA™ [Alpha-1 Proteinase Inhibitor (Human)], marking the first treatment for adult patients with emphysema due to severe AAT Deficiency that can be self-infused at home after appropriate training.
  • Announced a collaboration with myTomorrows to provide early access throughout Europe to Kamada’s proprietary Alpha-1 Antitrypsin (AAT) to treat bone marrow transplant patients who develop steroid refractory Graft-Versus-Host Disease (GvHD).
  • Appointed Naveh Tov, M.D., Ph.D., to the position of Vice President, Clinical Development and Medical Director for Pulmonary Diseases, where he will lead Kamada’s clinical development activities.

“The expanded label for GLASSIA allowing self-infusion at home was a significant milestone for Kamada that we believe will contribute significantly to further future growth,” continued Mr. London.  “We recently received from the European Medicines Agency their 120-Day List of Questions regarding the Company’s Marketing Authorization Application for our inhaled AAT to treat AAT deficiency, and expect to submit our full response in early 2017, and anticipate a regulatory decision on our regulatory submission in mid-2017.  We recently initiated discussions with the FDA and received preliminary feedback on the regulatory path forward in the U.S. for our inhaled AAT.   We will report the results of those discussions once they have concluded.” 

Second Quarter 2016 Financial Results Compared to Second Quarter 2015 Financial Results

Total revenues for the second quarter of 2016 were $19.1 million, compared to $19.2 million in the same period of 2015. Revenues from the Proprietary Products segment were $12.1 million, as compared to $12.7 million in 2015.  As the second quarter of 2015 included revenues delayed from the first quarter of 2015, we believe the six-month comparison between 2016 and 2015 is more representative of the growth in this segment.  Distributed Products revenue was $7.0 million, compared with $6.5 million in 2015.

Gross profit for the second quarter of 2016 grew to $5.6 million, compared with $3.6 million in the second quarter of 2015.  Gross margin increased to 30% from 19% in the same period of 2015.

R&D expenses in the second quarter of 2016 were $3.5 million, compared to $3.4 in 2015.  Selling, general and administrative expenses were $2.7 million, flat from the same period in 2015.  Operating loss in the second quarter of 2016 was $0.6 million, compared to an operating loss of $2.5 million in 2015.  The net loss for the second quarter of 2016 was $1.6 million, or $0.04 per diluted share, compared to a net loss of $2.3 million, or $0.06 per diluted share, in 2015.

Adjusted EBITDA for the second quarter of 2016 was $0.6 million, compared with a loss for the second quarter of 2015 of $1.1 million.  Adjusted net loss for the second quarter of 2016 was $1.3 million, compared with an adjusted net loss of $1.8 million in the second quarter of 2015.

Six Months Ended June 30, 2016 vs. June 30, 2015 Total revenues for the six months of 2016 were $33.9 million, compared to $28.2 million in the same period of 2015.  Revenues from the Proprietary Product segment for the six months of 2016 were $23.2 million, as compared to $15.9 million in the same period of 2015.  Distributed Products revenue was $10.6 million for the six months of 2016, compared with $12.3 million in the same period of 2015.

Gross profit for the six-month period of 2016 grew to $10.4 million, compared to $4.0 million during the six-month period of 2015.  Gross margin increased to 31% from 14% in the same period of 2015.

R&D expenses in the six-month period of 2016 were $7.6 million, compared to $7.1 million in the same period of 2015.  Selling, general and administrative expenses in the six-month period of 2016 were $5.4 million, compared to $5.2 million in the same period of 2015.  For the six-month period of 2016, we reported an operating loss of $2.6 million, compared with an operating loss of $8.2 million in the same period of 2015.  The net loss for the six months of 2016 was $3.9 million, or $0.11 per diluted share, compared with a net loss of $7.6 million, or $0.21 per diluted share, in the same period of 2015.

Adjusted EBITDA for the six months ended June 30, 2016, was a loss of $0.2 million, compared with a loss for the six months ended June 30, 2015, of $5.6 million.  Adjusted net loss for the six months ended June 30, 2016, was $3.2 million, compared with an adjusted net loss of $6.6 million in the six months ended June 30, 2015.

Balance Sheet Highlights As of June 30, 2016, the Company had cash, cash equivalents and short-term investments of $29.5 million, compared with $28.3 million as of December 31, 2015.   During the first half of 2016, the Company generated $1.0 million in cash from operations, used $1.5 million for capital expenditures and generated $1.6 million from financing activities, primarily loans to fund capital expenditures. During the second quarter of 2016, the Company used $6.5 million to fund operations. This change is a result of timing related to payments to suppliers and collections from customers.

2016 Revenue Guidance For the year ending December 31, 2016, Kamada continues to expect total revenues to be between $75 million and $80 million.

Conference Call Kamada management will host an investment community conference call today at 8:30 a.m. Eastern time to discuss these results and answer questions. Shareholders and other interested parties may participate in the conference call by dialing 888-427-9415 (from within the U.S.) or 719-325-2468 (from outside the U.S.) and entering the conference identification number: 7415234.

A replay of the call will be accessible beginning two hours after its completion through August 16, 2016 by dialing 877-870-5176 (from within the U.S.) or 858-384-5517 (from outside the U.S.) and entering the conference identification number: 7415234. The call will also be archived for 90 days at www.kamada.com .

About Kamada Kamada Ltd. is focused on plasma-derived protein therapeutics for orphan indications, and has a commercial product portfolio and a robust late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.  AAT is a protein derived from human plasma with known and newly-discovered therapeutic roles given its immunomodulatory, anti-inflammatory, tissue-protective and antimicrobial properties. The Company’s flagship product is Glassia®, the first and only liquid, ready-to-use, intravenous plasma-derived AAT product approved by the U.S. Food and Drug Administration. Kamada markets Glassia® in the U.S. through a strategic partnership with Baxalta (formerly Baxter International Inc.’s BioScience business and now part of Shire plc) and in other counties through local distributors.  In addition to Glassia®, Kamada has a product line of seven other pharmaceutical products administered by injection or infusion, that are marketed through distributors in more than 15 countries, including Israel, Russia, Brazil, India and other countries in Latin America and Asia. Kamada has five late-stage plasma-derived protein products in development, including an inhaled formulation of AAT for the treatment of AAT deficiency that its MAA was submitted to the EMA after completing a pivotal Phase 2/3 clinical trials in Europe and is in Phase 2 clinical trials in the U.S. In addition, Kamada's intravenous AAT is in development for other indications such as type-1 diabetes, GvHD and prevention of lung transplant rejection. Kamada also leverages its expertise and presence in the plasma-derived protein therapeutics market by distributing more than 10 complementary products in Israel that are manufactured by third parties.

Cautionary Note Regarding Forward-Looking Statements This release includes forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995.  Forward-looking statements are statements that are not historical facts, such as statements regarding assumptions and results related to financial results forecast, commercial results, timing and results of clinical trials and EMA and U.S. FDA authorizations.  Forward-looking statements are based on Kamada’s current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions.  Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, unexpected results of clinical trials, delays or denial in the U.S. FDA or the EMA approval process, additional competition in the AATD market or further regulatory delays.  The forward-looking statements made herein speak only as of the date of this announcement and Kamada undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.

         
Consolidated Balance Sheets
    As of June 30,   As of December 31,
      2016       2015       2015  
    Unaudited   Audited
    In thousands
Current Assets            
Cash and cash equivalents   $ 7,136     $ 6,807     $ 5,047  
Short-term investments     22,391       37,511       23,259  
Trade receivables, net     15,936       15,584       23,071  
Other accounts  receivables     3,475       4,408       2,881  
Inventories     28,423       24,785       26,336  
             
      77,361       89,095       80,594  
             
Non-Current Assets            
Property, plant and equipment, net     21,138       21,562       21,309  
Other long-term assets     73       103       89  
             
      21,211       21,665       21,398  
             
      98,572       110,760       101,992  
Current Liabilities Current maturities of loans and convertible debentures            
    392       7,924       37  
Trade payables     10,247       14,808       16,917  
Other accounts payables     6,068       3,385       4,064  
Deferred revenues     5,114       1,792       1,921  
             
      21,821       27,909       22,939  
             
Non-Current Liabilities            
Loans     1,537       -       151  
Employee benefit liabilities, net     402       693       787  
Deferred revenues     5,424       6,895       5,608  
             
      7,363       7,588       6,546  
Shareholder's Equity            
Ordinary shares of NIS 1 par value:                        
Authorized - 60,000,000 ordinary shares; Issued and outstanding – 36,418,741 and 36,387,929 shares at June 30, 2016 and 2015, respectively.     9,320       9,312       9,320  
Share premium     162,649       160,927       162,238  
Conversion option in convertible debentures     -       1,147       -  
Capital reserve due to translation to presentation currency     (3,490 )     (3,490 )     (3,490 )
Capital reserve from hedges     9       134       (1 )
Capital reserve from available for sale  financial assets     119       49       73  
Capital reserve from share-based payments     9,455       8,362       9,157  
Capital reserve from employee benefits     (59 )     (81 )     (59 )
Accumulated deficit     (108,615 )     (101,097 )     (104,731 )
      69,388       75,263       72,507  
    $ 98,572     $ 110,760     $ 101,992  
                         
Consolidated Statements of Comprehensive Income
    Six months period ended June 30,   Three months period ended  June 30,   Year ended December 31,
      2016       2015       2016       2015       2015  
    Unaudited   Audited
    In thousands (except for per-share data)
                     
Revenues from proprietary products   $ 23,226     $ 15,881     $ 12,106     $ 12,708     $ 42,952  
Revenues from distribution     10,637       12,295       6,960       6,538       26,954  
                     
Total revenues     33,863       28,176       19,066       19,246       69,906  
                     
Cost of revenues from proprietary products     14,410       12,930       7,479       9,635       30,468  
Cost of revenues from distribution     9,047       11,214       5,958       5,971       23,640  
                     
Total cost of revenues     23,457       24,144       13,437       15,606       54,108  
                     
Gross profit     10,406       4,032       5,629       3,640       15,798  
                     
Research and development expenses     7,609       7,058       3,502       3,415       16,530  
Selling and marketing expenses     1,691       1,743       856       944       3,652  
General and administrative expenses     3,674       3,437       1,861       1,737       7,040  
                     
Operating loss     (2,568 )     (8,206 )     (590 )     (2,456 )     (11,424 )
                     
                     
Financial income     298       300       133       114       463  
Income (expense) in respect of currency exchange and derivatives instruments, net     (59 )     761       90       248       625  
Financial expense     (67 )     (491 )     (30 )     (248 )     (934 )
Loss before  taxes on income     (2,396 )     (7,636 )     (397 )     (2,342 )     (11,270 )
Taxes on income     1,488       -       1,188       -       -  
                     
Loss     (3,884 )     (7,636 )     (1,585 )     (2,342 )     (11,270 )
                     
Other Comprehensive Income (loss):                    
Items that may be reclassified to profit or loss in subsequent periods:                    
Gain (loss) on available for sale financial assets     46       39       (25 )     (79 )     63  
Profit (loss) on cash flow hedges     80       194       (165 )     415       71  
Net amounts transferred to the statement of profit or loss for cash flow hedges     (70 )     56       (36 )     (16 )     44  
Items that will not be reclassified to profit or loss in subsequent periods:                    
Actuarial net gain of defined benefit plans     -       -       -       -       22  
Total comprehensive loss   $ (3,828 )   $ (7,347 )   $ (1,811 )   $ (2,022 )   $ (11,070 )
                     
Loss per share attributable to equity holders of the Company:                    
Basic loss per share   $ (0.11 )   $ (0.21 )   $ (0.04 )   $ (0.06 )   $ (0.31 )
                     
Diluted loss per share   $ (0.11 )   $ (0.21 )   $ (0.04 )   $ (0.06 )   $ (0.31 )
                                         
Consolidated Statements of Cash Flows
   Six months period Ended   Three months period Ended   Year Ended 
  June 30, June 30,  December 31, 
    2016       2015       2016       2015       2015  
  Unaudited Audited
  In thousands
 
Cash Flows from Operating Activities  
   
Net loss $ (3,884 )   $ (7,636 )   $ (1,585 )   $ (2,342 )   $ (11,270 )
           
Adjustments to reconcile loss to net cash provided by (used in) operating activities:          
           
Adjustments to the profit or loss items:          
           
Depreciation, amortization and impairment of equipment   1,709       1,572       878       801       3,227  
Finance income, net   (172 )     (570 )     (193 )     *(114 )     (154 )
Cost of share-based payment   709       1,029       328       524       1,907  
Income tax expense   1,488       -       1,188       -       -  
Loss from sale of property and equipment   10       -       -       -       -  
Change in employee benefit liabilities, net   (385 )     (29 )     (250 )     (46 )     87  
                                       
    3,359       2,002       1,951       1,165       5,067  
Changes in asset and liability items:                                      
           
Decrease (increase) in trade receivables, net   7,304       2,211       (6,955 )     (6,207 )     (5,604 )
Decrease  (increase) in other accounts receivables   147       (502 )     905       *102       118  
Decrease (increase) in inventories   (2,087 )     638       3,182       2,650       (913 )
Increase in deferred expenses   (774 )     (1,400 )     (304 )     (1,471 )     (565 )
Increase (decrease) in trade payables   (6,869 )     (1,461 )     (7,939 )     1,111       887  
Increase (decrease) in other accounts payables   726       (584 )     439       75       94  
Increase (decrease)  in deferred revenues   3,009       (1,247 )     3,975       (1,070 )     (2,405 )
           
    1,456       (2,345 )     (6,697 )     (4,801 )     (8,388 )
Cash received (paid) during the period for:          
Interest paid   (9 )     (243 )     (7 )     (122 )     (484 )
Interest received   424       594       138       244       1,143  
Taxes paid   (306 )     (47 )     (303 )     (18 )     (47 )
           
    109       304       (172 )     104       612  
           
Net cash provided by (used in) operating activities $ 1,040     $ (7,675 )   $ (6,503 )   $ (5,883 )   $ (13,979 )
                                       
*Reclassification                                      
                                       

 

Consolidated Statements of Cash Flows
   Six months period Ended   Three months period Ended  Year Ended
  June 30, June 30,  December 31, 
    2016       2015       2016       2015       2015  
  Unaudited Audited
  In thousands
 
Cash Flows from Investing Activities  
Proceeds from sale of (investment in) short term investments, net $ 776     $ 25     $ 1,392     $ (400 )   $ 13,971  
Purchase of property and equipment   (1,469 )     (1,332 )     (543 )     (823 )     (2,718 )
Proceeds from sale of property and equipment   21       -       -       -       -  
                                       
Net cash provided by (used in) investing activities   (672 )     (1,307 )     849       (1,223 )     11,253  
                                       
Cash Flows from Financing Activities                                      
Proceeds from exercise of warrants and options   -       1,165       -       * 949       1,254  
Receipt of long-term loans   1,701       -       1,071       -       197  
Repayment of long-term loans   (61 )     -       (50 )     -       (9 )
Repayment of convertible debentures   -       -       -       -       (7,797 )
                                    -  
Net cash provided by (used in) financing activities   1,640       1,165       1,021       949       (6,355 )
                                       
Exchange differences on balances of cash and cash equivalent   81       78       164       *(47 )     (418 )
                                       
Increase (decrease) in cash and cash equivalents   2,089       (7,739 )     (4,469 )     (6,204 )     (9,499 )
                                       
Cash and cash equivalents at the beginning of the period   5,047       14,546       11,605       13,011       14,546  
                                       
Cash and cash equivalents at the end of the period $ 7,136     $ 6,807     $ 7,136     $ 6,807     $ 5,047  
                                       
Significant non-cash transactions                                      
Purchase of property and equipment through capital lease $ 84     $ -     $ -     $ -     $ -  
                                       
                                       
*Reclassification                                      
                                       
Adjusted EBITDA
    Six months period Ended June 30,   Three months period Ended June 30,   For the year Ended December 31,  
      2016       201 5       2016       2015       2015  
                                           
    In thousands
                     
Net loss   $ (3,884 )   $ (7,636 )   $ (1,585 )   $ (2,342 )   $ (11,270 )
Income tax expense     1,488       -       1,188       -       -  
                     
Financial expense (income), net     (172 )     (570 )     (193 )     (114 )     (154 )
                     
Depreciation and amortization expense     1,709       1,572       878       801       3,227  
                     
Share-based compensation charges     709       1,029       328       524       1,907  
                     
Adjusted EBITDA   $ (150 )   $ (5,605 )   $ 616       (1,131 )   $ (6,290 )
                                         
Adjusted net income
    Six months period Ended June 30,   Three months period Ended June 30,   For the Year Ended December 31,
      2016       201 5       2016       2015       2015  
    In thousands
                     
Net loss   $ (3,884 )   $ (7,636 )   $ (1,585 )   $ (2,342 )   $ (11,270 )
                     
Share-based compensation charges     709       1,029       328       524       1,907  
                     
Adjusted Net loss   $ (3,175 )   $ (6,607 )   $ (1,257 )   $ (1,818 )   $ (9,363 )
                                 

CONTACT: Gil Efron Chief Financial Officer ir@kamada.com Bob Yedid LifeSci Advisors 646-597-6989 bob@lifesciadvisors.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

HLTH USA 2026 Spotlights AI and Health Innovation

Updated Category News Views 12

The Pulse of Innovation at HLTH USA 2026 Diving headfirst into the heart of healthcare innovation, HLTH USA 2026 kicked off with gusto in Las Vegas. Discussions are swirling around AI advancements and the next generation of payer-provider collaboration. Who knew healthcare could be this thrilling? The event is already shaping up to be a powerhouse of change, buzzing with...

Continue Reading
Sasol AGM Resolutions Passed in One Swift Swing

Updated Category News Views 44

Sasol's AGM Delivers Smooth Sailing for Shareholders Can't say I'm surprised, but Sasol's annual general meeting on the 13th of November went off without a hitch—unless, of course, you're one of those folks who just loves fireworks at these gatherings. The entire set of resolutions danced through with a resounding "Aye," making it one heck of a day for anyone banking on...

Continue Reading
Jones Soda Expands into Nutrition with UCAN Deal

Updated Category News Views 59

Well, Jones Soda Co. (CSE: JSDA) is stirring the pot with its recent move to acquire the UCAN functional nutrition assets. Popped the news on November 12, 2026, and it turns out they've shelled out a cool $700,000 in cash and taken on $500,000 in liabilities for the privilege. This isn't some casual shuffle of dollars and cents—this one's a strategic gambit aimed at...

Continue Reading
WHP Global's Japan Move: A Major Toy Market Play

Updated Category News Views 0

New Horizons for Toys"R"Us in Japan Well, folks, look who's back in the toy game with a vengeance! WHP Global is shaking hands with Pan Pacific International Holdings (PPIH) to breathe new life into Toys"R"Us across Japan. Now PPIH isn’t just any player. We're talking about Japan's fourth-largest retailer, helming giants like Don Quijote and aiming to crown itself as...

Continue Reading
Sue Egstrand to Lead Karo's Next Growth Phase

Updated Category News Views 64

A New Captain at Karo’s Helm Karo Healthcare is bracing for an exciting ride. Sue Egstrand’s appointment as the new CEO pulls the curtain on what might just be a game-changing era for the company. Set to take the wheel on January 1, 2027, Egstrand brings a heavy-hitting resume—a mash-up of pharmaceutical prowess and a deep-dive into consumer healthcare. Sue’s...

Continue Reading
LONGi's Four Paths to Global Green Development

Updated Category News Views 149

LONGi's Vision: A Cleaner, Greener Future Amidst the buzz at COP31 in Antalya, LONGi is making waves with promises of a cleaner future. They're not just throwing around eco-friendly slogans—this company's laying down real pathways to tackle climate change, one solar panel at a time. Aiming for Industrial Transformation LONGi's got their sights set on shaking up...

Continue Reading
Univers Partners to Propel Physical AI Across Industries

Updated Category News Views 95

Univers Sets Sights on Global Physical AI Expansion Now here's a tune we've been humming for a while—AI is coming to take over the mundane, and Univers seems to think it's got the right band together to make that a full-blown concert in the built environment. Announced right in the heart of Antalya, Türkiye, at the esteemed COP31, we're seeing Univers grab hands with...

Continue Reading
Stark Future Amasses €150M, Revving Up Electric Bike Dominance

Updated Category News Views 115

Well, if you've been keeping your eye on electric vehicles, this is a story that might raise those eyebrows. Stark Future, a name perhaps not buzzing on every street just yet, has gone and done it—snagged over €150 million in fresh capital. Breaking Barriers with Record-breaking Numbers Stark Future didn't just make a ripple; they caused a tsunami. This buzzing...

Continue Reading
Engrain's Geospatial Innovation Pushes Property Mapping Forward

Updated Category News Views 45

Pushing the Boundaries of Property Mapping How far can you expand the boundaries of property mapping tech? Well, Engrain seems hell-bent on finding out by cranking their innovations up a notch. The Denver-based stalwart in interactive mapping is rolling out some mind-boggling enhancements that could redefine how the multifamily housing sector operates. This isn't just...

Continue Reading
Dawson Struggles With Q3 Losses Despite Growth Prospects

Updated Category News Views 25

Profit and loss dance around like a jittery stock, and Dawson Geophysical is feeling the heat this third quarter. Numbers are in, and we’re seeing a net loss of $5.2 million, translating to $0.17 per share—ouch. Not to mention a negative Adjusted EBITDA of $2 million. Compared to last year's hopes, that's a serious belly flop. Revenue Down, Hopes Up In a fetching...

Continue Reading

Top 5 Most Recently Viewed Articles

BD Unveils Advanced Hemodynamic Monitoring Solution to Aid Clinicians

Updated Category News Views 225

Revolutionizing Patient Monitoring with AI Technology BD (Becton, Dickinson and Company) (NYSE: BDX) has introduced a groundbreaking hemodynamic monitoring solution known as the HemoSphere Alta™ Advanced Monitoring Platform. This innovative system incorporates predictive algorithms powered by artificial intelligence (AI), designed to assist clinicians in managing blood...

Continue Reading
James Talarico's Bold Stand Against Elon Musk's Pay Package

Updated Category News Views 395

Texas Representative James Talarico's Critique of Billionaire Wealth Rep. James Talarico from Texas has recently made headlines with his pointed criticism of Tesla's CEO, Elon Musk, regarding the approval of his staggering new trillion-dollar compensation package. Talarico emphasized the pressing issue of income disparity in the wealthiest nation. The Inequity in Wealth...

Continue Reading
Priority Technology Holdings, Inc. Reaches New Heights in Market

Updated Category News Views 84

Recent Surge in Priority Technology Holdings Stock Priority Technology Holdings, Inc. (PRTH) has made headlines recently as its stock reached a remarkable 52-week high, hitting $9.89. This surge exemplifies a dramatic turnaround for the company, with its stock value experiencing a striking climb over the past year. Investors have been vigilant about PRTH's trajectory, and...

Continue Reading
Lokal Homes Unveils Exciting New Lots in Jackson Creek Community

Updated Category News Views 272

Introducing New Homes at Jackson Creek Lokal Homes, a renowned homebuilder in Colorado, is thrilled to announce the upcoming launch of its latest community, Jackson Creek. Nestled in stunning foothills, this new community promises to bring exceptional living spaces to prospective homebuyers. The grand opening is set for a future date, and it is already generating...

Continue Reading
Understanding the Drop in Hims & Hers Health Stock Today

Updated Category News Views 89

The Factors Behind Hims & Hers Health's Stock Decline Hims & Hers Health Inc shares have faced a downturn in trading, largely influenced by market dynamics involving competitors. The decline appears to be a reaction to news surrounding Eli Lilly and Company, a major player in the pharmaceutical sector. Recent Developments with Eli Lilly Recent announcements from the U.S....

Continue Reading